Literature DB >> 15728300

Reasons for exclusion from thrombolytic therapy following acute ischemic stroke.

D Cocho1, R Belvís, J Martí-Fàbregas, L Molina-Porcel, J Díaz-Manera, A Aleu, J Pagonabarraga, D García-Bargo, A Mauri, J-L Martí-Vilalta.   

Abstract

Despite evidence for the efficacy of thrombolytic therapy in acute ischemic stroke, only 1 to 7% of patients receive this therapy. The authors sought to determine the reasons for exclusion from tissue plasminogen activator (tPA) in an acute setting and found avoidable causes in 18% of patients. Improvements in intrahospital coordination would increase the number of patients who might benefit from tPA treatment at the authors' center.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15728300     DOI： 10.1212/01.WNL.0000152041.20486.2F

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  35 in total

1.  17β-estradiol attenuates breakdown of blood-brain barrier and hemorrhagic transformation induced by tissue plasminogen activator in cerebral ischemia.

Authors:  Mingchang Li; Zhan Zhang; Weiyun Sun; Raymond C Koehler; Judy Huang
Journal:  Neurobiol Dis       Date:  2011-07-18       Impact factor: 5.996

Review 2.  Imaging in Endovascular Stroke Trials.

Authors:  Konark Malhotra; David S Liebeskind
Journal:  J Neuroimaging       Date:  2015 Jul-Aug       Impact factor: 2.486

3.  Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial.

Authors:  Felipe de Los Ríos la Rosa; Jane Khoury; Brett M Kissela; Matthew L Flaherty; Kathleen Alwell; Charles J Moomaw; Pooja Khatri; Opeolu Adeoye; Daniel Woo; Simona Ferioli; Dawn O Kleindorfer
Journal:  Stroke       Date:  2012-03-22       Impact factor: 7.914

4.  Combining MRI with NIHSS thresholds to predict outcome in acute ischemic stroke: value for patient selection.

Authors:  P W Schaefer; B Pulli; W A Copen; J A Hirsch; T Leslie-Mazwi; L H Schwamm; O Wu; R G González; A J Yoo
Journal:  AJNR Am J Neuroradiol       Date:  2014-09-25       Impact factor: 3.825

5.  [Reality of acute stroke patient care in the metropolitan Ruhr area: status quo and perspectives of a stroke-specific network].

Authors:  J Eyding; M Kitzrow; D Bartig; H-U Sorgenfrei; C Krogias
Journal:  Nervenarzt       Date:  2012-12       Impact factor: 1.214

6.  Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials.

Authors:  Pooja Khatri; Dawn O Kleindorfer; Sharon D Yeatts; Jeffrey L Saver; Steven R Levine; Patrick D Lyden; Charles J Moomaw; Yuko Y Palesch; Edward C Jauch; Joseph P Broderick
Journal:  Stroke       Date:  2010-09-02       Impact factor: 7.914

7.  Too good to treat? Outcomes in patients not receiving thrombolysis due to mild deficits or rapidly improving symptoms.

Authors:  Joshua Z Willey; Joshua Stillman; Juan A Rivolta; Julio Vieira; Margaret M Doyle; Guillermo Linares; Adrian Marchidann; Mitchell S V Elkind; Bernadette Boden-Albala; Randolph S Marshall
Journal:  Int J Stroke       Date:  2011-11-22       Impact factor: 5.266

Review 8.  Use of magnetic resonance imaging to predict outcome after stroke: a review of experimental and clinical evidence.

Authors:  Tracy D Farr; Susanne Wegener
Journal:  J Cereb Blood Flow Metab       Date:  2010-01-20       Impact factor: 6.200

9.  Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke.

Authors:  N S Rost; S Masrur; M A Pervez; A Viswanathan; L H Schwamm
Journal:  Neurology       Date:  2009-11-25       Impact factor: 9.910

10.  Poststroke neuronal rescue and synaptogenesis mediated in vivo by protein kinase C in adult brains.

Authors:  Miao-Kun Sun; Jarin Hongpaisan; Thomas J Nelson; Daniel L Alkon
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-03       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.